Vivani Medical, Inc. ( (VANI) ) has released its Q2 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vivani Medical, Inc. is a biopharmaceutical company specializing in the development of miniaturized, ultra long-acting drug implants, primarily targeting chronic diseases such as obesity and type 2 diabetes. The company has recently announced a $10 million equity financing to accelerate the development of its semaglutide implant, NPM-139, following promising preclinical and clinical study results. Vivani’s financial results for the second quarter of 2025 showed a net loss of $7.1 million, with increased research and development expenses contributing to the loss. The company is also planning to spin off its division, Cortigent, Inc., as an independent publicly traded entity. Looking ahead, Vivani aims to initiate clinical development of NPM-139 in 2026, with a focus on advancing its pipeline of drug implants to provide innovative therapeutic solutions for chronic conditions.